BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

Retrospective, observational study to understand the effectiveness of alogliptin on glycaemic variability through continuous glucose monitoring (cgm) in t2dm indian patients: a real-world evidence

Authors:Suhas Gopal Erande, Abhijit Trailokya *, Amar Shirsat
Int J Biol Med Res. 2024; 15(4): 7877-7880  |  PDF File

Abstract

Aim: This study aimed to assess effectiveness of Alogliptin 25 mg on Glycaemic variability (GV) through continues glucose monitoring (CGM) in patients with T2DM in retrospective observational real-world settings. Materials and Methods: 15 patients who received Alogliptin over existing anti-diabetic treatment as routine clinical practice in management of T2DMf were analysed retrospectively from single centre. Data collected from past medical records. FreeStyle Librepro 1.0.6 was used for CGM. CGM was done 15 days prior to adding Alogliptin and repeated approximately after 3 weeks that for next 15 days. Percentage time in target range (TIR) (70- 180mg/dl), Percentage time above target and Percentage time below target,and Mean BG levelwere assessed prior and after adding Alogliptin in existing treatment regimen. Results:Significant improvement seen in Percentage time in target range (TIR) (70-180mg/dl) from 65% to 80% (+15% P value 0.00037) and significant reduction seen in Percentage time above target from 32% to 16% (- 16%, P valve 0.0002). There is non-significant increase in Time below Therapeutic range from 3% to 5% (+2%, P=0.3116.).Significant reduction in Average blood glucose level seen after adding Alogliptin in existing treatment regimen from 157 mg/dl to 134 mg/dl (-23 mg/dl, P0.00034). Conclusion: Alogliptin was found to be effective and well tolerated when added to the patients who were uncontrolled on other oral anti-diabetic medications. It effectively showed improvement in continues glucose monitoring (CGM) parameters like Time in therapeutic range (TIR) and significant improvement seen in glycaemic variability.